- Home
- MNOV vs CRVO Comparison
MNOV vs CRVO Comparison
Compare MNOV & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | CRVO |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 78.5M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | CRVO |
|---|---|---|
| Price | $1.61 | $7.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.00 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 92.3K | 58.0K |
| Earning Date | 02-18-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,917.00 | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $1.92 |
| 52 Week High | $2.06 | $16.94 |
Technical Indicators
Market Signals| Indicator | MNOV | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 37.66 |
| Support Level | $1.43 | $6.90 |
| Resistance Level | $1.52 | $8.22 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 93.59 | 14.10 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.